These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 33737697

  • 1. Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.
    Emamifar A, Ellingsen T, Hermann AP, Hess S, Gerke O, Ahangarani Farahani Z, Syrak Hansen P, Jensen Hansen IM, Thye-Rønn P.
    Sci Rep; 2021 Mar 18; 11(1):6220. PubMed ID: 33737697
    [Abstract] [Full Text] [Related]

  • 2. Polymyalgia rheumatica and giant cell arteritis-three challenges-consequences of the vasculitis process, osteoporosis, and malignancy: A prospective cohort study protocol.
    Emamifar A, Hess S, Gerke O, Hermann AP, Laustrup H, Hansen PS, Thye-Rønn P, Marcussen N, Svendstrup F, Gildberg-Mortensen R, Bang JC, Farahani ZA, Chrysidis S, Toftegaard P, Andreasen RA, le Greves S, Andersen HR, Olsen RN, Hansen IMJ.
    Medicine (Baltimore); 2017 Jun 18; 96(26):e7297. PubMed ID: 28658131
    [Abstract] [Full Text] [Related]

  • 3. The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis.
    Jakobsson K, Jacobsson L, Mohammad AJ, Nilsson JÅ, Warrington K, Matteson EL, Turesson C.
    BMC Musculoskelet Disord; 2016 Aug 24; 17(1):363. PubMed ID: 27558589
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [A case of giant cell arteritis after prednisolone dose reduction during treatment of polymyalgia rheumatica].
    Yamashita M, Aoki A, Kobayashi H, Wakiya M, Nakatsugawa M.
    Nihon Ronen Igakkai Zasshi; 2023 Aug 24; 60(4):440-447. PubMed ID: 38171762
    [Abstract] [Full Text] [Related]

  • 7. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica.
    van Sleen Y, Boots AMH, Abdulahad WH, Bijzet J, Sandovici M, van der Geest KSM, Brouwer E.
    Rheumatology (Oxford); 2020 Jan 01; 59(1):176-184. PubMed ID: 31292652
    [Abstract] [Full Text] [Related]

  • 8. Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue.
    Manning JE, Harris E, Mathieson H, Sorensen L, Luqmani R, McGettrick HM, Morgan AW, Young SP, Mackie SL.
    J Autoimmun; 2024 Jul 01; 147():103260. PubMed ID: 38797046
    [Abstract] [Full Text] [Related]

  • 9. Do statins decrease vascular inflammation in patients at risk for large-vessel vasculitis? A retrospective observational study with FDG-PET/CT in polymyalgia rheumatica, giant cell arteritis and fever of unknown origin.
    Iannuzzi F, Hysa E, Camellino D, Morbelli S, Bauckneht M, Sambuceti G, Cutolo M, Cimmino MA.
    Clin Exp Rheumatol; 2023 Apr 01; 41(4):812-820. PubMed ID: 37073635
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
    Albrecht K, Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, Thiele K, Zink A.
    Rheumatol Int; 2018 Apr 01; 38(4):569-577. PubMed ID: 29124397
    [Abstract] [Full Text] [Related]

  • 13. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
    Kyle V, Hazleman BL.
    Ann Rheum Dis; 1989 Aug 01; 48(8):658-61. PubMed ID: 2782975
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
    Martinez-Taboada VM, Bartolome MJ, Fernandez-Gonzalez MD, Blanco R, Rodriguez-Valverde V, Lopez-Hoyos M.
    Rheumatology (Oxford); 2003 Sep 01; 42(9):1055-61. PubMed ID: 12730520
    [Abstract] [Full Text] [Related]

  • 19. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.
    Diamantopoulos AP, Hetland H, Myklebust G.
    Biomed Res Int; 2013 Sep 01; 2013():120638. PubMed ID: 24106691
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.